Afectación pulmonar rápidamente progresiva secundaria a dermatomiositis juvenil anti-MDA5(+) con evolución devastadora

Núñez Cuadros, Esmeralda; Galindo Zavala, Rocío; Martín Pedraz, Laura; García Soler, Patricia.
An. pediatr. (2003. Ed. impr.) ; 96(4): 378-380, abril 2022. ilus
Artículo en Español | IBECS (España) | ID: ibc-205473

Documentos relacionados

  1. Anti-MDA5-associated dermatomyositis.
  2. [A CASE OF CLINICALLY AMYOPATHIC DERMAMYOSITIS WITH INTERSTITIAL LUNG DISEASE SHOWING TWO DETERIORATIONS IN 4 YEARS].
  3. Efficacy and Safety of Tofacitinib in Anti-Melanoma Differentiation-Associated 5 Gene Antibody-Positive Dermatomyositis.
  4. [Complete atrioventricular block as the first manifestation of dermatomyositis].
  5. Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort.
  6. Efficacy and safety of apremilast in a patient with paraneoplastic dermatomyositis with resistant skin disease.
  7. Clinical characteristics and management of clinically amyopathic juvenile dermatomyositis across four academic centers.
  8. Superior Mesenteric Artery Syndrome in a Case of Juvenile Dermatomyositis: A Unique Complication.
  9. Relapsing retroperitoenal abscess secondary to juvenile dermatomyositis: Complexity in management.
  10. A case series of hydroxychloroquine exacerbating the dermatomyositis rash.